Sangamo Therapeutics Business Update
Sangamo Therapeutics filed amended monthly operating reports (MORs) for July and August 2026, along with a new MOR for September 2026, as part of its ongoing Chapter 11 bankruptcy proceedings. The reports provide updated cash balances, receipts, and disbursements required by the Bankruptcy Court but are not prepared in accordance with GAAP. The company's common stock was recently delisted from Nasdaq and currently trades on the OTC Expert Market.